Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|4|314-319

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.4, 2015-04, pp. : 314-319

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immortal time bias and reverse causality in retrospective analysis: Comment on “effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib–melphalan–prednisone in the phase III VISTA study”

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 8, 2015-08 ,pp. : E146-E146

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma

By  

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 229-230

Karger

Access to resources Recommend Favorite

Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 1, 2018-01 ,pp. : 10-19

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti-Angiogenic Effect of Bortezomib in Patients with Multiple Myeloma

By  

Acta Haematologica, Vol. 114, Iss. 3, 2005-10 ,pp. : 170-173

Karger

Access to resources Recommend Favorite

The effects of bortezomib on bone disease in patients with multiple myeloma

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 618-623

John Wiley & Sons Inc

Access to resources Recommend Favorite